The Top 5 Biosimilar Articles for the Week of June 21

Here are the top 5 biosimilar articles for the week of June 21, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 21, 2021.

Number 5: The Supreme Court ruled that plaintiffs had no standing to challenge the constitutionality of the Affordable Care Act, saving the Biologics Price Competition and Innovation Act (BPCIA), which is the regulatory pathway for biosimilar approvals.

Number 4: Sophia Z. Humphreys, PharmD, MHA, explained how biosimilar utilization management can enable health care institutions to put COVID-19–related financial wreckage behind them.

Number 3: Real-world studies demonstrated comparable safety for trastuzumab biosimilars (Kanjinti and Zedora) vs the originator (Herceptin) and were presented at the ASCO 2021 Annual Meeting.

Number 2: Positive findings were reported for use of a bevacizumab biosimilar (Byvasda) in combination with sintilimab as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).

Number 1: The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contended.

To read all of these articles and more, visit centerforbiosimilars.com.